A multicentre phase 1b/2 study of tivozanib in patients with advanced inoperable hepatocellular carcinoma
Open Access
- 10 February 2020
- journal article
- research article
- Published by Springer Nature in British Journal of Cancer
- Vol. 122 (7) , 963-970
Abstract
Background: Hepatocellular carcinoma (HCC) is a major cause of cancer-related death. It is a highly vascular tumour with multiple angiogenic factors, most importantly vascular endothelial growth factor (VEGF), involved in HCC progression. Tivozanib is an oral inhibitor of VEGFR-1/2/3 with promising activity against HCC in vivo.Methods: We conducted a phase 1b/2 study of tivozanib in patients with advanced HCC. The safety, dosing, pharmacokinetics, pharmacodynamics, and preliminary antineoplastic efficacy of tivozanib were evaluated.Results: Twenty-seven patients received at least one dose of tivozanib. Using a 3+3 design, the recommended phase 2 dose (RP2D) of tivozanib was determined to be 1 mg per os once daily, 21 days on–7 days off. The median progression-free and overall survival were 24 weeks and 9 months, respectively, for patients treated at RP2D. The overall response rate was 21%. Treatment was well tolerated. A significant decrease in soluble plasma VEGFR-2 was noted, assuring adequate target engagement.Conclusions: Although this study did not proceed to stage 2, there was an early efficacy signal with a very favourable toxicity profile. A phase 1/2 trial of tivozanib in combination with durvalumab is currently underway.Trial registration: ClinicalTrials.gov NCT01835223, registered on 15 April 2013.Keywords
Funding Information
- This study was approved and funded by the National Comprehensive Cancer Network (NCCN) Oncology Research Program from general research support provided by AVEO Pharmaceuticals, Inc
This publication has 38 references indexed in Scilit:
- Abstract 752: The effect of food on the pharmacokinetics of tivozanib2012
- Biologic and Clinical Activity of Tivozanib (AV-951, KRN-951), a Selective Inhibitor of VEGF Receptor-1, -2, and -3 Tyrosine Kinases, in a 4-Week-On, 2-Week-Off Schedule in Patients with Advanced Solid TumorsClinical Cancer Research, 2011
- Management of Hepatocellular Carcinoma: An Update ΔσHepatology, 2011
- Abstract A12: Variation in response to triple VEGFR inhibitor tivozanib in mouse models of hepatocellular carcinomaMolecular Cancer Therapeutics, 2009
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Multi-Kinase Inhibitor E7080 Suppresses Lymph Node and Lung Metastases of Human Mammary Breast Tumor MDA-MB-231 via Inhibition of Vascular Endothelial Growth Factor-Receptor (VEGF-R) 2 and VEGF-R3 KinaseClinical Cancer Research, 2008
- Sorafenib in Advanced Hepatocellular CarcinomaNew England Journal of Medicine, 2008
- KRN951, a Highly Potent Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases, Has Antitumor Activities and Affects Functional Vascular PropertiesCancer Research, 2006
- BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and AngiogenesisCancer Research, 2004
- Spontaneous Tumor-Specific Humoral and Cellular Immune Responses to NY-ESO-1 in Hepatocellular CarcinomaClinical Cancer Research, 2004